Notice NOT-FD-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-076 from the NIH Guide for Grants and Contracts

Notice NOT-AR-17-017 from the NIH Guide for Grants and Contracts

Notice NOT-TR-17-018 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-17-317 from the NIH Guide for Grants and Contracts. These administrative supplements provide funds to awarded P30 Environmental Health Sciences Core Centers to enhance interactions across Centers to address emerging issues and to advance research, translation, and community engagement.

Funding Opportunity RFA-DA-18-011 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse supported a number of HIV/AIDS cohorts among substance abusing populations. These cohorts address emerging and high priority research on HIV/AIDS. These longitudinal cohorts serve as a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research. Accomplishments by the NIDA-funded cohorts have been highly significant. Four of these cohorts (see below) will be terminated within a year if continued support is not provided. Therefore, the purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to support the maintenance and expansion of these NIDA-funded cohorts to continue to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance abuse. This FOA will provide continued support for recruiting and retaining participants in the cohort(s) to provide insight into the changing demographics of the HIV epidemic among this high risk population in the United States (U.S.). This FOA will also continue to provide a strong resource platform for current and future collaborative efforts with other investigators to address new and emerging questions related to HIV infection, prevention, and/or treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research goals.

Notice NOT-DK-17-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-17-030 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-031 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-18-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic research to elucidate the impact of microenvironment, which includes cellular components of the niche, extracellular matrix, and soluble factors, on lung progenitor cell phenotype and function during development, homeostasis, repair and regeneration. Multi-disciplinary teams with complementary expertise are encouraged to propose innovative, hypothesis-based studies to catalyze this understudied area critical to advancing lung stem cell biology. This FOA will also support the development of novel 3-dimensional, multi-component models to interrogate lung stem cell niches.

Notice NOT-HL-17-519 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-068 from the NIH Guide for Grants and Contracts

Notice NOT-AA-17-006 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-316 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources (BTRR). These Resources conduct research and development of new or improved technologies driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Resources technologies and experimental results. Resources should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. New applicants are strongly encouraged to submit a pre-application in response to PAR-17-315 The pre-application process provides feedback on whether the proposed technology development is appropriate for the NIGMS BTRR program, and the potential competitiveness of a full application.

Funding Opportunity PAR-17-315 from the NIH Guide for Grants and Contracts. This announcement encourages pre-applications for the creation of national Biomedical Technology Research Resources (BTRRs). These Resources develop new or improved technology driven by the needs of basic, translational, and clinical researchers. The BTRRs are charged to make their technologies available to the biomedical research community, to train members of this community in the use of the technologies, and to disseminate both the technologies and the Resources experimental results broadly.

Funding Opportunity PAR-17-313 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.

Funding Opportunity PAR-17-314 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.

Notice NOT-AI-17-029 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-17-311 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html and the HHS National Viral Hepatitis Action Plan 2017-2020: https://www.hhs.gov/hepatitis/blog/2017/01/19/updated-national-viral-hepatitis-action-plan-2017-2020.html

Funding Opportunity RFA-FD-18-002 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to support the implementation of NEST through operations of the NEST CC toward sustainable operations for the future to coincide with the stated purposes and goals listed in Section IV.H of the draft Medical Device User Fee Act Performance Goals and Procedures, Fiscal Years 2018 Through 2022 letter (MDUFA IV Commitment Letter, Available at https://www.fda.gov/downloads/ForIndustry/UserFees/MedicalDeviceUserFee/UCM526395.pdf